ArticleHaematologica2023

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.

Keith W Pratz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.